Fund Details
Overview
Investment portfolio
34rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Novadip Biosciences | Sep 2026Participated | $12 MOther Equity | |
Ona Therapeutics | Jun 2026Participated | $87 MSeries B | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Tubulis | Oct 2025Participated | $357 MSeries C | |
Coave Therapeutics | Jan 2025Participated | $37 MSeries A | |
Confo Therapeutics | Jul 2024Participated | $65 MSeries B | |
Tubulis | Mar 2024Participated | $140 MSeries B | |
Novadip Biosciences | Nov 2022Participated | $24 MSeries B | |
Etherna | Aug 2022Participated | $39 MSeries B | |
AstriVax | Aug 2022Led | $30 MSeed | |
Minoryx Therapeutics | May 2022Participated | $55 MSeries C | |
Tubulis | May 2022Participated | $63 MSeries B | |
Novadip Biosciences | Sep 2026Participated | $12 MOther Equity | |
Ona Therapeutics | Jun 2026Participated | $87 MSeries B | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Tubulis | Oct 2025Participated | $357 MSeries C | |
Coave Therapeutics | Jan 2025Participated | $37 MSeries A | |
Confo Therapeutics | Jul 2024Participated | $65 MSeries B | |
Tubulis | Mar 2024Participated | $140 MSeries B | |
Novadip Biosciences | Nov 2022Participated | $24 MSeries B | |
Etherna | Aug 2022Participated | $39 MSeries B | |
AstriVax | Aug 2022Led | $30 MSeed | |
Minoryx Therapeutics | May 2022Participated | $55 MSeries C | |
Tubulis | May 2022Participated | $63 MSeries B |
34 Items
34
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 2 | 8 |
| Series B | 3 | 13 |
| Series C+ | 0 | 3 |
| Other Equity | 2 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '15 | 1 |
| Oct '15 | 1 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 1 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 1 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 2 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 3 |
| Jul '20 | 2 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 2 |
| Nov '21 | 0 |
| Dec '21 | 1 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 2 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 2 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 1 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 31 |
| Networks, Cloud & Communication | 2 |
| Crypto & Blockchain | 2 |
| Media & Entertainment | 2 |
| Space & Frontier Tech | 2 |
| Hardware & Robotics | 1 |
| Manufacturing | 1 |
| E-Commerce & Retail | 1 |
| Cybersecurity & Privacy | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 6 |
| $25M-$50M | 17 |
| $50M-$100M | 8 |
| $100M-$250M | 2 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 30 |
| United States | 4 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| SRIW | 10 |
| EQT Life Sciences (LSP) | 9 |
| VIVES Louvain Technology Fund | 7 |
| PMV | 6 |
| V-Bio Ventures | 6 |
| Andera Partners | 5 |
| BNP Paribas Fortis Private Equity | 4 |
| Bpifrance | 4 |
| High-Tech Grunderfonds | 4 |
| New Science Ventures | 4 |
| Omega Funds | 4 |
| SFPI | 4 |
| SFPI-FPIM | 4 |
| VIB | 4 |
| Ysios Capital | 4 |
| Ackermans & van Haaren | 3 |
| Bayern Kapital | 3 |
| BioGeneration Ventures | 3 |
| BioMedPartners | 3 |
| Boehringer Ingelheim | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 8 | 24% |
| Participating | 26 | 76% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 63% |
| Co-led | 3 | 38% |
Team
Desire Collen
Founder & Chairman
Philippe Monteyne
Partner
